Last updated on July 2018

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics


Brief description of study

The primary objective is to characterize the pharmacokinetics of single doses of ceftobiprole in neonates and infants aged 3 months. The secondary objective is to evaluate safety and tolerability of ceftobiprole in neonates and infants aged 3 months.

Clinical Study Identifier: NCT02527681

Contact Investigators or Research Sites near you

Start Over

Kamal Hamed, MD, MPH

University Children's Hospital of Krak w
Kraków, Poland
  Connect »